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ABSTRACT: 
Background: Prostate cancer is one of the most common cancers in the world. There are genetic 
and environmental factors that can potentially impact the development and progression of many 
types of cancer, including prostate cancer. As a consequence of environmental factors, such as 
diet having a potential effect on the development of prostate cancer, considerable interest in the 
possible health benefits associated with the inclusion and consumption of certain foods in the 
diet exists.  
 
Context and purpose of this study: This study describes the effects of a proanthocyanidin-
enriched fraction (PACs) isolated from the American cranberry (Vaccinium macrocarpon) on the 
behaviour of androgen-refractory (insensitive) DU145 human prostate cancer cells in vitro.  
 
Results: Following treatment of DU145 human prostate cancer cells with 25 µg/mL of PACs for 
six hours, PACs significantly decreased the cellular viability of DU145 cells. PACs treatment 
(25 µg/mL for 6 hours) of DU145 cells increased the proportion of cells in the G2-M phase of 
the cell cycle and decreased the proportion of cells in the G1 phase of the cell cycle. These 
alterations were associated with changes in cell cycle regulatory proteins and other cell cycle 
associated proteins. PACs increased the expression of cyclin E, cyclin D1, CDK2 and CDK4, 
and decreased the expression of cyclin A and cyclin B1. The protein expression level of p27 
increased,  and  the  protein  expression  levels  of  p16
INK4a,  p21,  and  pRBp107  decreased  in 
response  to  PACs  treatment.  The  protein  expression  level  of  pRBp130  was  unchanged  in Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 131 of 146 
response to PACs treatment.  
 
Conclusions: These findings demonstrate that proanthocyanidins from the American cranberry 
can affect the behaviour of human prostate cancer cells in vitro and further support the potential 
health benefits associated with cranberries. 
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INTRODUCTION:  
Prostate cancer is one of the major health concerns in the Western world [1]. Therefore, research 
studies focused on determining and describing the etiology and development of prostate cancer, 
and for the treatment of prostate cancer, including possible chemo-preventative and/or chemo-
protective  strategies,  is  warranted.  The  risk  of  developing  many  types  of  cancer,  including 
prostate cancer, is associated with genetics. Environmental factors may also determine whether 
cancer will develop [2]. In this regard, the rates of prostate cancer are much lower in East Asian 
countries as compared to North America [3]. Interestingly, post-migration to North America and 
the risk for East Asian men developing prostate cancer increases for both themselves and their 
descendants suggesting an environmental role for the development of prostate cancer [4]. The 
nature of the diet has also been implicated in affecting the development and/or progression of 
prostate cancer [5,6]. 
Considerable  interest  in  examining  the  effects  of  whole  extracts  and  their  constituent 
phytochemicals from a wide variety of different foods upon the behaviour of cancer cells both in 
vitro and in vivo have arisen. In this regard, many phytochemicals have been shown to have 
substantial effects on the behaviour of prostate cancer cells [7-14]. 
Our research focuses on phytochemicals isolated from the American cranberry (Vaccinium 
macrocarpon) fruit. Previously, we have demonstrated that constituents from cranberries can 
induce and regulate apoptosis and also affect the activity of many key proteins, such as the 
matrix  metalloproteinases,  associated  with  the  metastatic  potential  of  cancer  in  androgen-
insensitive (DU145) human prostate cancer cells [11-13]. Due to the cranberry phytochemical 
extracts’  ability  to  affect  apoptosis,  it  was  previously  hypothesized  that  extracts  from  the 
American cranberry could cause cell cycle arrest in DU145 human prostate cancer cells.   Cell 
cycle deregulation is a common occurrence in cancer, leading to uncontrolled and unmitigated 
cell growth and division, and compounds which effect the expression of cell cycle proteins may 
be a method of controlling or preventing the growth of cancer [15]. The proteins assayed in this 
study represent an overview of the cell cycle, with cyclins and cyclin dependent kinases working 
in conjunction to push the cell cycle forward and the cell cycle inhibitory proteins retarding this 
process [16]. Whole extracts from the cranberries have previously been demonstrated to affect 
human prostate cancer cell growth via cell cycle arrest by modulating expression of these cell 
cycle regulatory proteins [16]. In this current study, the effects of a proanthocyanidin–enriched 
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through the cell cycle, and the expression of key cell cycle associated proteins are examined in 
DU145 human prostate cancer cells in vitro. 
 
MATERIALS AND METHODS: 
Experimental Materials: All antibodies used in this study were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). They include: anti-actin, anti-CDK2, anti-CDK4, anti-
cyclin A, anti-cyclin B1, anti-cyclin D1, anti-cyclin E, anti-p21, anti-p27, anti-p16
INK4a, anti-
pRBp107,  and  anti-pRBp130.  Reagent-grade  acetone,  methanol,  and  ethyl  acetate  were 
purchased from Pharmco Products Inc. (Brookfield, CT). Solvents for HPLC analysis were from 
Fisher Scientific. Diaion
® HP-20 was from Supelco, Inc. (Bellefonte, PA), and Sephadex™ LH-
20 was from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). Procyanidin A2 was from 
Indofine  Chemical  Company  (Hillsborough,  NJ).  All  other  chemicals  and  materials  were 
purchased as indicated. 
 
Preparation  of  Cranberry  Proanthocyanidin-Enriched  Fraction  (PACs):  Cranberry  fruit 
(Vaccinium  macrocarpon)  was  harvested  in  November  2009  at  the  State  Bog  in  Wareham, 
Massachusetts. The fruit was flash-frozen in liquid nitrogen and stored at -20
oC until use. For 
preparation of whole cranberry polyphenolic extract, 1.04 kg of fruit was macerated in 300 mL 
solvent in a Waring Blender for five minutes, and then allowed to stand for thirty minutes. The 
slurry was  filtered, and the solids  were blended with  several  additional 100 mL portions  of 
solvent until the solids were nearly colorless. An additional extraction with 200 mL of ethyl 
acetate was performed; the filtrates were concentrated by rotary evaporation and freeze-dried, 
then re-dissolved in a minimum volume of distilled water and chromatographed on Diaion HP-
20 resin (5.5 x 30 cm) to remove free sugars. Extracts were allowed to adsorb the resin for fifteen 
minutes. The column was washed with 2 L distilled water to remove sugars and organic acids, 
and then eluted with 100% methanol. The eluate concentrated in vacuo and freeze-dried to yield 
7.11  g  de-sugared  crude  whole  cranberry  extract.  Proanthocyanidins  were  isolated  using  a 
published procedure [17]. Briefly, 0.508 g crude extract was dissolved in a minimum volume of 
distilled water and applied to a Sephadex LH-20 column packed in 70:30 methanol/water (3 x 22 
cm). Elution, first with 600 mL of 70:30 methanol/water, removed phenolic acids, anthocyanins, 
and flavonol glycosides as colored bands. Then the elution with 100 mL 70:30 acetone/water 
yielded a fraction that was dried in vacuo to give 132 mg of tan solid. HPLC analysis on a 
Waters XTerra C8 column, using a published procedure [17], was used to verify the presence of 
procyanidin A2, other epicatechin oligomers with characteristic absorbance at 279.1 nm, the 
absence of characteristic anthocyanin (520 nm), and flavonol (355 nm) peaks. The presence of 
(epi)catechin oligomers of up to 12 degrees of polymerization was verified by MALDI-TOF MS 
analysis  at  the  University  of  Massachusetts  Amherst  Spectroscopic  Facility,  as  described 
previously [17]. 
 
Cell  Culture  and  Treatment  with  Proanthocyanidin-Enriched  Fraction  (PACs):  Human 
DU145 prostate adenocarcinoma cells (ATCC, Manassas, VA) were cultured on 100 mm plastic 
tissue  culture  dishes  (Falcon,  Mississauga,  ON)  in  alpha  minimal  essential  media  (MEM) Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 133 of 146 
(Gibco, Burlington, ON) and also supplemented with 10% fetal bovine serum (FBS) (Invitrogen 
Canada, Burlington, ON.) and 1% antibiotic-antimycotic (Invitrogen Canada, Burlington, ON). 
Cells (4 x 10
5) were cultured on the tissue culture dishes and were initially incubated for twenty-
four hours at 37
oC in the presence of 5% CO2. After this 24-hour incubation period, the media 
was  removed  and  replaced  with  serum  free  alpha  MEM  supplemented  with  5  µg/mL  of 
transferrin (Sigma) and 2.5µg/mL of insulin (Sigma). The use of the serum-free medium (defined 
medium) was to ensure that the effects noted were due to the effects of the PACs and not due to 
any possible interactions that may have occurred between the PACs and the components of the 
serum. These plates were again incubated for  twenty-four hours at 37
oC in the presence of 5% 
CO2.  After  this  incubation  period,  cells  were  treated  with  PACs  to  a  final  concentration  of 
25µg/ml for six hours. PACs were dissolved in dimethyl sulfoxide (DMSO) as the vehicle prior 
to use. The control cells received only the vehicle (DMSO) at a concentration of 0.1%; the 
concentration of DMSO used in the control cells is the same as the concentration of DMSO 
introduced to  treated  cells  (as  the vehicle  for PACs) and DMSO  alone has  previously been 
determined to have no effect on these cells at this concentration. After treatment, the media was 
removed from the cells and stored at -80
oC for further analysis. The cells were then washed with 
PBS and were removed by trypsin (Sigma) diluted in phosphate buffered saline (PBS). The cells 
were  re-suspended with alpha MEM  supplemented with  10% FBS and were  centrifuged for 
fourminutes at 500 x g. After centrifugation, the cell pellet was re-suspended with PBS, then was 
transferred to a micro centrifuge tube, and was centrifuged at 500x g for four minutes. After 
centrifugation, this cell pellet was then stored at -80
oC until subsequent immunoblot analysis as 
described below. 
 
Cellular Growth Curve: DU145 cells (25,000 cells/plate) were cultured on tissue culture plates 
in alpha-MEM supplemented with 10% FBS and 1% antibiotic/antimycotic solution. Following 
twenty-four  hours  of  cell  culture,  cells  were  counted  using  a  haemocytometer,  and  the  cell 
number was determined. This cell count represented the zero-time point. The cells were then 
cultured  in  the  presence  of  alpha  MEM  containing  1%  FBS  and  1%  antibiotic/antimycotic 
solution  supplemented  with  either  DMSO  (vehicle)  or  25  µg/mL  PACs.  Cell  numbers  were 
evaluated  following  a  further  twenty-four,  forty-eight,  and  seventy-two  hours  of  cell  culture 
respectively. Triplicate plates were evaluated for each treatment at each time point. 
 
Alamar Blue Cytotoxicity Assay: The Alamar Blue assay (Invitrogen, Burlington, ON) was 
used to determine cellular viability after treatment with PACs as per manufacturer’s instructions. 
Briefly, DU145 cells were sub-cultured into a ninety-six well plate at 5,000 cells/well. After 
twenty-four hours of incubation, the media was replaced with 100µl of serum-free media and 
was once again incubated for twenty-four hours. After this incubation, the cells were treated with 
PACs for six hours with a final concentration of DMSO within each well of 0.1%. The control 
for this experiment was DU145 cells treated with DMSO alone at a total concentration of 0.1% 
for six hours. Following treatment, 10µl of Alamar Blue was added to each well. The cells were 
incubated for three hours post exposure to Alamar Blue. After this three-hour incubation period, Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 134 of 146 
the resulting fluorescence was read with an excitation wavelength of 528 nm and an emission 
wavelength of 590 nm. 
 
Immunoblot  Analyses:  Protein  expression  was  determined  in  the  whole  cytosolic  protein 
fraction. Briefly, cell pellets were reconstituted in 100 µl of 10 mM Tris-HCl buffer (pH 7.4) 
containing 0.5 mM PMSF (Sigma). Once re-constituted, the cells were then sonicated. The cell 
lysates were then centrifuged for ten minutes at 9,300 g at 4
oC. Following this centrifugation, the 
supernatant was removed from the pellet, and this “cytosolic lysate” fraction was subsequently 
evaluated. Equal amounts of protein extracts from lysates were mixed in a 3:1 ratio with standard 
Laemmili buffer consisting of 50 mM Tris-HCl (pH 6.8), 10% SDS, 0.1% bromophenol blue, 
10% glycerol, and 100mM beta-mercaptoethanol. Once mixed, these samples were boiled for 
three minutes. Once boiled, they were resolved by electrophoresis through 10% SDS-PAGE gels 
and  transferred  onto  nitrocellulose  membranes  (Biorad).  After  transfer,  the  membranes  were 
incubated in the presence of a 1% BSA (w/v) TBS-Tween (0.05% v/v) solution for one hour at 
room temperature. The membranes were then incubated with primary antibodies diluted to a 
1:200 ratio (v/v). The membranes were incubated in the presence of the primary antibody for 
twenty-four hours at 4˚C. After incubation, the membranes were washed three times with TBS-
Tween  (0.05%)  for  ten  minutes  and  were  incubated  in  alkaline  phosphatase-conjugated 
secondary antibodies (1:2000 dilution) for one hour. After incubation, the membranes were again 
washed three times with TBS-Tween (0.05%)  for ten minutes, washed briefly  with  distilled 
water, and then exposed to SigmaFast BCIP-NBT tablets (Sigma) in solution to visualize protein 
expression levels. Western blots were then analyzed using Infinity Capture software (Lumenera 
Corp., Ottawa, ON), and densitometry was performed with ImageJ software (National Institute 
of Health, Bethesda, MD). 
 
Flow cytometry for cell cycle analysis: DU145 cells treated with either 0.1% DMSO (control) 
or treated with 25 µg/mL for six hours were harvested with trypsin and then washed with alpha 
MEM containing 10% FBS. The final concentration of DMSO in the PACs treatments was also 
0.1%. The cells were then centrifuged for five minutes at 200x g at room temperature. Once 
centrifuged, the media was removed, and the cells were re-suspended in 25 µl of PBS, which 
were then placed in 225 µl of 70:30 ethanol:PBS mixture and allowed to fix for two hours on ice. 
The  fixed  cells  were  then  centrifuged  for  five  minutes  at  200x  g  at  4˚C  and  were  then  re-
suspended in 250 µl of ice-cold PBS for five minutes. The cells were then re-centrifuged for five 
minutes at 200 x g at 4˚C, and the cell pellet was then suspended in a PBS propidium iodide (the 
propidium  iodide  was  used  at  a  final  concentration  of  0.02  mg/mL  (w/v))  (Sigma)  staining 
solution with Triton-X (Sigma) (which was added at a concentration of 0.09% (v/v)) and 0.4 
mg/ml of RNAse (Sigma) and were incubated for thirty minutes at room temperature in the dark. 
Once incubated, the cells were transferred into a ninety-six round bottom well plate and were 
analysed  using  a  BD  FACSARRAY  bio-analyzer  equipped  with  BD  FACSARRAY  system 
software version 1.0.3 (BD Biosciences, Mississauga, ON). The results of this analysis were 
processed using WinMDI software version 2.9 (Scripps Research Institute, La Jolla, CA). Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 135 of 146 
Statistical  Analysis:  Statistical  analysis  was  done  using  GraphPad  Prism  for  Windows 
(GraphPad Software Inc. San Diego, CA) by using an unpaired t-test. Results are expressed with 
either a statistical significance of p<0.05 (**) or a statistical significance of p<0.10(*). 
 
RESULTS 
Characterization  of  the  proanthocyanidin-enriched  fraction  (PACs):  The  composition  of 
extractable PACs from whole cranberry fruit had been described previously (12-14). MALDI-
TOF MS analysis of the PACs fraction was performed and is presented in Figure 1. As shown in 
Figure 1, the MALDI-TOF MS analysis of the PACs fraction confirmed the presence of A-linked 
PACs of between 2-12 degrees of polymerization, as previously reported for cranberry PACs 
preparations (14-15). Briefly, the masses detected the major constituents of the fraction to be 
epicatechin dimer (M + Cs = 709 amu confirmed as procyanidin A2 by HPLC comparison to 
commercial standard), trimer (M + Cs = 997 amu), tetramer (M + Cs = 1285) pentamer (M + Cs 
= 1573 amu), and hexamer (M + Cs = 1861 amu), each containing one A-type linkage as well as 
smaller  amounts  of  the  larger  oligomers  (data  not  shown).  The  bio-availability  of  these 
compounds to the prostate has not been established.  
 
Figure  1:  MALDI-TOF  mass  spectrum  of  the  cranberry  proanthocyanidin  (PACs) 
fraction.Major peaks represent [M+Cs] of (epi)catechin oligomers with degree of polymerization 
(DP) as shown. 
 
PACs are cytotoxic to DU145 human prostate cancer cells in vitro: The effects of PACs on 
DU145 human prostate cancer cells were measured by Alamar Blue assay. As shown in Figure 2, 
PACs  significantly  decreased  the  viability  of  these  cells  at  a  dose  of  25  µg/mL.  Viability 
decreased by approximately 30% in response to 25 µg/mL of PACs treatment of DU145 cells for 
six  hours.  This  concentration  of  25  µg/mL  PACs  was  chosen  for  further  study,  as  it  was 
determined previously to be the effective concentration which was able to exert a substantial 
effect  on  the  behaviour  of  DU145  cells  in  vitro  [12,13,18].  Furthermore,  in  time  course Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 136 of 146 
experiments, the growth of DU145 cells, in response to PACs, was found to be inhibited (Figure 
3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: PACs treatment of DU145 cells affects cellular viability. DU145 cell viability was 
evaluated by Alamar Blue assay following treatment with 25 µg/mL of PACs for six hours. 
Control cells received 0.1% DMSO (vehicle) for six hours. Fluorescence was read at 528 nm 
(excitation) and 590 nm (emission) wavelengths. Control cell viability was set to 100% viability. 
Treatment with PACs (25 µg/mL) for six hours significantly decreased the viability of DU145 
cells relative to control cells, which denotes a P-value of <0.10 (*).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: PACs treatment of DU145 cells affects their growth. DU145 cells were cultured in the 
presence of either 0.1% DMSO (vehicle) (control) or 25 µg/mL PACs for twenty-four, forty 
eight, and seventy-two hours respectively. The number of cells present under these treatment 
conditions  was  determined. Triplicate plates  were evaluated  for  each treatment  at  each time 
point. 
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PACs increases the number of DU145 cells in the G2-M phase and decreases the number of 
DU145 cells in the G1 phase of the cell cycle: To further investigate the effects of PACs on 
DU145 cells, flow cytometric analysis was conducted to ascertain if PACs treatment of DU145 
cells affected cell cycle progression. As shown in Figures 4A and 4B, after treatment with 25 
µg/mL for six hours, PACs increased the number of cells in the G2-M phase of the cell cycle and 
decreased the number of cells in the G1 phase of the cell cycle. The first image in Figure 4A 
represents  one  experiment  with  vehicle  treated  cells  (0.1%  DMSO),  and  the  second  image 
represents one experiment with DU145 cells treated with 25 µg/mL PACs. The summary of flow 
cytometric replicates is illustrated in Figure 4B. PACs treatment of DU145 cells with 25 µg/mL 
PACs for six hours results in a block in the G2-M phase of the cell cycle. 
 
 
Figure 4: Flow cytometric analysis of DU145 cells treated with vehicle (0.1% DMSO) and 25 
µg/mL of PACs for six hours. PACs significantly increases the number of cells in the G2-M 
phase (b) of the cell cycle and decreases the number of cells in the G1 phase (a) of the cell cycle. 
Data shown in Figure 4A is from a representative experiment. Figure 4B is histograms which 
indicate the results of cell cycle analysis of DU145 cells in the presence of PACs (at 25 µg/mL) 
and shows that PACs significantly effects the distribution of cells which denotes a P value of 
<0.05 (**). Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 138 of 146 
Effects of PACs treatment on expression of cell cycle related proteins in DU145 prostate 
cancer cells: As shown in Figure 5, the expression of cyclin A and cyclin B1 protein levels in 
DU145 prostate cancer cells decreased response to treatment with 25 µg/mL PACs for six hours. 
The protein expression levels of cyclin E, cyclin D1, CDK2, and CDK4 increased following 
treatment of DU145 cells with 25 µg/mL PACs for six hours (Figure 5). To ascertain why the 
expression levels of these proteins were affected by the PACs treatment, the protein expression 
levels of some key cell cycle inhibitors were also examined.  
         As shown in Figure 6, after treatment of DU145 cells with 25µg/mL of PACs for six hours, 
the protein expression level of p27 increased whereas the protein expression levels of p16
INK4a, 
p21, and pRBp107 decreased. However, the protein expression level of pRBp130 was apparently 
unaffected by 25 µg/mL PACs as it remained unchanged.  
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Figure 5A and 5B: PACs effects the expression of cell cycle proteins in DU145 cells. Cells 
were treated with either vehicle (0.1% DMSO) or with 25 µg/mL PACs for six hours. Figure 5A: 
CDK2, CDK4, cyclin A, cyclin B1, cyclin D1, and cyclin E protein expression levels are shown. 
Actin was used as a loading control. Each blot shown is representative of results obtained from 
three separate experiments with assay triplicates. Figure 5B: Histograms illustrating the protein 
expression  levels  in  response  to  PACs  treatment.(*)  Denotes  a  P  value  of  <  0.10,  and  (**) 
denotes a P-value of <0.05. Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 140 of 146 
 
Figure 6A and 6B: PACs effects the protein expression levels of cell cycle protein inhibitors. 
DU145 cells were treated with either vehicle (0.1% DMSO) or with 25 µg/mL PACs for six 
hours. Figure 6A: p16
INK4a, p21, p27, p107, and p130 protein expression levels are shown. Actin Functional Foods in Health and Disease 2014; 4(2):130- 146                                                           Page 141 of 146 
was used as a loading control. Each blot shown is representative of results obtained from three 
separate  experiments  with  assay  triplicates.  Figure  6B:  Histograms  illustrating  the  protein 
expression levels in response to PACs treatment. (**) Denotes a P value of <0.05. 
 
DISCUSSION: 
In  this  investigation,  the  effects  of  PACs  from  the  American  cranberry  (Vaccinium 
macrocarpon) on the behaviour of DU145 human prostate cancer cells in vitro were determined. 
PACs were able to induce cytotoxicity at 25 µg/mL after six hours to modulate the expression of 
several cell cycle associated proteins and to slow the progression of DU145 cells through the cell 
cycle. The PACs concentration used was previously demonstrated to be able to affect a number 
of cellular activities in the DU145 cells, including the expression of matrix metalloproteinase and 
the induction of apoptosis in vitro [12,18]. Cranberry PACs are also able to target both ovarian 
cancer  cell  viability  and  angiogenesis  in  vitro  [19].  This  may  suggest  that  such  PACs 
concentrations  may  be  physiologically  relevant.  However,  whether  these  concentrations  are 
attainable in the prostate in vivo remains to be determined. A further confounding factor is that in 
an in vivo situation, it is most probably the metabolites of the PACs that are impacting upon the 
behaviour of the prostate. What these metabolites are and how they act on the prostate remains 
undetermined. 
Previously, we have shown that a whole cranberry extract (WCE) is able to affect human 
prostate cancer  cell  growth via cell cycle  arrest  by modulating  expression of key  cell cycle 
proteins and their associated cellular regulators [16]. WCE treatment of DU145 cells decreased 
the proportion of cells in the G2-M phase of the cell cycle and increased the proportion of cells 
in the G1 phase of the cell cycle following treatment with WCE for six hours [16]. This G1 
phase  increase  is  also  seen  in  SEG-1  human  esophageal  adenocarcinoma  cells  treated  with 
cranberry  proanthocyanidins  for  twenty-four  and  forty-eight  hours  [20]  as  well  as  human 
epidermoid carcinoma A431 cells treated with dietary grape seed proanthocyanidins (containing 
exclusively B-linked oligomer) [21] and a number of head and neck squamous cell carcinomas 
treated with grape seed proanthocyanidins [22]. Oligomeric proanthocyanidin complexes (OPC) 
have been shown to exert anti-proliferative and pro-apoptotic effects on human prostate cancer 
cells [23]. In this regard, treatment of androgen responsive LNCaP prostate cancer cells with 
OPC resulted in a decrease in the number of LNCaP cells in the S-phase of the cell cycle and an 
increase in the number of cells in the sub G1 phase [23].  
However, the PACs effect was the opposite with PACs increasing the proportion of cells in 
the G2-M phase of the cell cycle and decreasing the proportion of cells in the G1 phase of the 
cell cycle. In keeping with this observation, grape proanthocyanidins have been shown to inhibit 
pancreatic cancer cell growth in vitro and this reduced cellular viability was associated with 
increased G2/M phase arrest of the cell cycle, which led to the induction of apoptosis [24]. 
Likewise,  purified  cranberry  proanthocyanidins  (PAC-1A)  caused  pro-apoptotic  effects  and 
cytotoxicity in high-risk neuroblastoma cells, and this was in association with PAC-1A’s ability 
to  partially  block  the  cell  cycle  in  G2/M  phase  with  a  concomitant  decrease  in  the  G0-G1 
population  [25].  PAC-1  treatment  of  SKOV-3  ovarian  cancer  cells  also  blocked  cell  cycle 
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block seen in DU145 cells is consistent with these findings. It  would appear that the PACs 
mediated  cell  cycle  alterations/responses  may  be  cell–type  dependent  and  perhaps  time 
dependent as well. 
Previously,  we  have  reported  that  several  alterations  in  expression  levels  of  cell  cycle 
activities  occurred  in  response  to  WCE  treatment  of  DU145  cells  [16].  WCE  decreased  the 
expression of CDK4, cyclin A, cyclin B1, cyclin D1 and cyclin E [16]. Unlike what occurred in 
response to WCE, only cyclin A and cyclin B1 protein expression levels decreased in response to 
PACs  treatment  of  DU145  cells,  whereas  cyclin  D1  and  cyclin  E  protein  expression  levels 
increased. An overview of the cell cycle is provided by Schwartz and Shah [26] wherein the 
functions of the various cyclins and cyclin dependent kinases are explained: cyclins D1 and E in 
conjunction with CDK2 and 4 drive the cell cycle from G1 to S phase, here cyclin A works with 
CDK2 to progress to G2 where cyclin B1 causes the cell cycle to enter the M phase. In another 
study, PAC-1 treatment of neuroblastoma cells resulted in an increase in cyclin D1 expression 
[25]. On the other hand, grape seed proanthocyanidin treatment of epidermoid carcinoma cells 
was associated with inhibition of cyclins D1, D2 and cyclin E [21]. In response to treatment of 
DU145 cells with WCE, p27 protein expression levels increased while CDK2 and p21 protein 
expression levels were apparently unaffected [16]. This is not what occurred in response to PACs 
treatment where protein expression of p27, CDK2, and CDK4 in DU145 cells increased and p21 
protein expression decreased. These proteins, p21 and p27, act as inhibitors of the cell cycle and 
specifically target  the CDKs  [26]. Grape seed  proanthocyanidin treatment  of head and neck 
squamous cell carcinoma cells resulted in inhibition of cyclin-dependent kinases (CDK) and 
increased  expression  of  the  CDK  inhibitory  proteins  Cip1/p21  and  Kip1/p27  [22].  Grape 
proanthocyanidin  treatment  of  human  non-small  cell  lung  cancer  cells  is  associated  with 
increased expression of Cip1/p21 and Kip1/p27 and a simultaneous decrease in the expression of 
CDKs  and cyclins  [27]. The cranberry proanthocyanidin treatment  of  neuroblastoma cells  is 
associated  with  up-regulation  of  cyclin  D1  and  a  down-regulation  of  CDK6  and  p27  [25]. 
Oligomeric proanthocyanidin complexes (OPC), extracted from either grape seeds or maritime 
pine bark, were found to inhibit expression of CDKs and cyclins and to stimulate expression of 
p21 and p27 in LNCaP and PC3 human prostate cancer cells [23]. 
Previously, we have demonstrated that WCE treatment of DU145 cells resulted in decreased 
p16
INK4a and increased pRBp107 protein expression levels with no apparent change in pRBp130 
[16]. The INK4 family of proteins and pRB family of proteins all represent cell cycle inhibitors 
with the potential to inhibit cell cycle progression. The INK4 family targets cyclin dependent 
kinases necessary for progression through G1 phase of the cell cycle [28]. The phytochemical 
apigenin is able to affect the behaviour of DU145 cells by inducing cell cycle arrest and by 
inducing apoptosis, this apigenin-mediated effect has been suggested to involve an increase in 
INK
4a/p16 in addition to alterations in other cell cycle-related activities [29]. When DU145 cells 
were treated with cranberry PACs, p16
INK4a and pRBp107 protein expression levels decreased 
and no apparent change occurred in pRBp130 expression. The pRB protein is a phosphorylated 
protein product required for cell cycle progression and regulation of its expression can be altered 
in  cancer  cells  [30].  Hypophosphorylation  of  RBp107  and  RB2p130  occurs  in  response  to 
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in response to PACs treatment may be of biological significance since a molecular link between 
cellular senescence/aging, and the suppression of tumour growth has been suggested to involve 
the p16
INK4a-RB signalling pathway [32]. In summary, cranberry PACs are cytotoxic to DU145 
human prostate cancer cells in vitro, and PACs are able to elicit a G2-M phase cell cycle effect 
associated with this cytotoxicity. This PACs associated cell cycle alteration occurs concomitant 
with alterations in expression levels of a number of cell cycle associated proteins. The precise 
reasons  why WCE  and  the PACs  have different  effects  on the cell  cycle and its  associated 
activities remains to be elucidated. However, it may be that the non-flavonoid constituents of 
WCE  are  responsible  for  the  type  of  cell  cycle  alterations  seen  in  response  to  WCE.  Such 
constituents would be absent in the purified flavonoids /PACs and as such, the effects on cell 
cycle and its associated activities would be different.  
 The  WCE-mediated  cyto-toxicity  in  DU145  cells  was  previously  shown  to  involve 
apoptosis [13]. PACs treatment of DU145 cells also result in an induction of apoptosis [18]. This 
PACs induced apoptosis is in keeping with other studies that have shown a cell cycle arrest and 
concomitant induction of apoptosis. In this regard, cranberry PACs have also been shown to 
induce a G2-M phase arrest in SKOV-3 ovarian cancer cells and to induce apoptosis through 
activation  of  both  the  intrinsic  and  extrinsic  pathways  of  apoptosis  [19].  Purified  cranberry 
proanthocyanidins can also cause pro-apoptotic signalling in high-risk neuroblastoma cells [25]. 
Oligomeric proanthocyanidins complexes (from grape seeds or maritime pine bark) have been 
suggested to exert pro-apoptotic effects in androgen sensitive LNCaP prostate cancer cells and in 
androgen-refractory PC3 prostate cancer cells [23]. Proanthocyanidins have also been suggested 
to, in addition to modulating cellcycle, induce apoptosis in several cell lines including head and 
neck squamous cell carcinomas, pancreatic cancer cells, and colon cancer cells [22, 24, 33]. 
The nature of the event that leads to the cell cycle alterations by PACs may involve an 
apoptosis-related event, which may impact upon a specific transcription factors that, in turn, 
would alter the expression of key cellular regulatory activities. In this regard, proanthocyanidins 
isolated from cranberry have been shown to inhibit the expression of matrix metalloproteinases 
in DU145 cells, and this inhibition has been shown to involve, at least in part, a decreased 
translocation of NFkB p65 protein to the nucleus [12]. The exact role of the transcription factors 
involved, if there is one, in the PACs-mediated alterations in cell cycle of DU145 prostate cancer 
cells remains to be elucidated. 
 
CONCLUSIONS: 
This  study  demonstrates  the  cell  cycle  inhibitory  effects  of  proanthocyanidins  on  hormone 
refractory  (insensitive)  DU145  human  prostate  cancer  cells.  The  effects  of  other  specific 
enriched fractions and metabolites of cranberry fruit on cell cycle events need to be examined in 
order to determine the exact nature of the phytochemicals present in the whole cranberry extract 
responsible for the observed alterations  in  DU145 cell behaviour. Such studies  are ongoing. 
Finally, this study revealed many novel effects of proanthocyanidins on DU145 cells, which we 
suggested may represent a potential source of novel phytochemical anti-cancer agents. As such, 
more research is warranted to determine the mechanisms by which cranberry and its constituents 
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Abbreviations:  BCIP:  5-bromo-4-chloro-3-indolyl-phosphate, CDK:  cyclin-dependent  kinase, 
Cip:CDK-interacting protein, DMSO:dimethyl sulfoxide, FBS: fetal bovine serum, HPLC: high-
performance  liquid  chromatography,  INK:  inhibitor  of  CDK,  Kip:  kinase  inhibitory  protein, 
MALDI-TOF MS: matrix-assisted laser desorption/ionization time of flight mass spectrometry, 
MEM:  minimal  essential  media,  OPC:  oligomeric  proanthocyanidin  complex,  PAC: 
proanthocyanidin, PBS: phosphate buffered saline, PMSF: phenylmethanesulfonylfluoride, RB: 
retinoblastoma protein, SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis, 
WCE: whole cranberry extract. 
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